Clinical trials: Metabolic Evaluation
Phenylketonuria
Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
- Trial name
- NCT00924703
- Testing
- rAvPAL-PEG
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- BioMarin Pharmaceutical
Elective Colonoscopy
Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep®
The purpose of this dose finding/comparative efficacy study is to first single out the most appropriate dose of mannitol for bowel preparation (phase II) and, subsequently, demonstrate the non-inferiority of the efficacy of…
- Trial name
- SATISFACTION (NCT04759885)
- Testing
- Phase II: NTC015 low dose, Phase II: NTC015 medium dose, Phase II: NTC015 high dose
- Where
- 35 sites in France, Germany and 2 more
- Volunteers
- 886 people
- Sponsor
- NTC srl
Diabetes Mellitus, Type 2
First Time in Human Study Using GSK2330672
The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.
- Trial name
- NCT01416324
- Testing
- 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.
- Trial name
- AWARD-6 (NCT01624259)
- Testing
- LY2189265, Liraglutide, Metformin
- Where
- 57 sites in United States, Czechia and 8 more
- Volunteers
- 599 people
- Sponsor
- Eli Lilly and Company
Healthy Participants Study, Overweight and Obese Adults
A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults.
- Conditions
- Healthy Participants Study, Overweight and Obese Adults, First in Man Study to Evaluate Initial Safety
- Trial name
- NCT07721597
- Testing
- ZP6590, solution for injection
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Myocardial Ischemia
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately…
- Trial name
- NCT00099788
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6,560 people
- Sponsor
- Gilead Sciences
Child Nutrition Disorders, Child Malnutrition
ESj- Powder Complete T&A Study
The goal of this study is to gather data on the tolerance and acceptability of a new ONS (ESj-powder complete) in children currently taking ONS.
- Trial name
- ESj (NCT04488718)
- Testing
- EnergieShake® Junior Powder Complete
- Where
- 3 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Anaiah Healthcare Pvt Ltd
Type 2 Diabetes
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.
- Trial name
- NCT06256549
- Testing
- GZR18, Semaglutide
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes Mellitus
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.
- Trial name
- NCT00888238
- Testing
- sitagliptin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension, Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group…
- Trial name
- FIESTA (NCT03338426)
- Testing
- Fimasartan 120mg, Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 133 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes Mellitus (T2DM)
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving…
- Trial name
- NCT07628985
- Testing
- Bofanglutide, Semaglutide
- Where
- 7 sites in Mexico
- Volunteers
- 374 people
- Sponsor
- Carnot Laboratories
Healthy Subjects, Hyperlipidemia, Hypertriglyceridemia
First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
ISH0688 is a human IgG1 Fc-FGF21 fusion protein. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and…
- Trial name
- NCT07505043
- Testing
- ISH0688 for injection
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Hyperlipidemia
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
The study is being conducted to evaluate the efficacy and safety of HRS-7249 for patients with hyperlipidemia, and to explore the reasonable dosage of HRS-7249 for patients with hyperlipidemia.
- Trial name
- NCT07100418
- Testing
- HRS-7249 Injection, Sodium Chloride Injection
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Post-Menopausal Osteoporosis
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP)…
- Trial name
- NCT03432533
- Testing
- romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
- Where
- 46 sites in United States, Poland and 1 more
- Volunteers
- 283 people
- Sponsor
- Amgen
Diabetes Type 2
Janagliflozin Treat T2DM Monotherapy
The purpose of this study is to assess the effect of Janagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 24 weeks of treatment, and to assess the efficacy after 52 weeks of treatment, overall safety and…
- Trial name
- NCT03811548
- Testing
- Janagliflozin 25mg, Janagliflozin 50mg
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Type 1 Diabetes
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy.
- Trial name
- NCT02463097
- Testing
- Insulin Pump
- Where
- 10 sites in United States, Israel
- Volunteers
- 124 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
- Trial name
- NCT01734785
- Testing
- Linagliptin, Empagliflozin + Linagliptin
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 607 people
- Sponsor
- Boehringer Ingelheim
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
- Trial name
- NCT03001817
- Testing
- K-877, Fenofibrate
- Where
- 220 sites in United States, Belarus and 7 more
- Volunteers
- 551 people
- Sponsor
- Kowa Research Institute, Inc.
Type 2 Diabetes
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients.
- Trial name
- SPOTLIGHT (NCT07456774)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient…
- Trial name
- NCT05318326
- Testing
- Yogliptin 400mg group, Yogliptin 200mg group
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.